Sarepta Therapeutics, Inc. is an American biotechnology company focused on the discovery and development of RNA-targeted therapeutics. The company's lead product candidate is eteplirsen, a treatment for Duchenne muscular dystrophy (DMD). The company is also developing other RNA-targeted therapeutics for the treatment of other neuromuscular and infectious diseases. Sarepta Therapeutics was founded in 1980 as AntiVirals, Inc. and changed its name to AVI BioPharma, Inc. in 2000. The company changed its name to Sarepta Therapeutics, Inc. in 2012.